Alzheon Announces Patent Issuance in Japan for ALZ-801 in Development for Alzheimer’s Disease

LEXINGTON, Mass., September 5, 2014 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the Japan Patent Office has issued a patent directed to the company’s lead product candidate ALZ-801. The allowed claims of this patent cover composition of matter of ALZ- 801 and methods of treating Alzheimer’s disease and other disorders using ALZ-801. This patent will provide protection in Japan until at least October 2027. The Japanese patent issuance follows the issuance of patents directed to ALZ-801 in the United States.

ALZ-801 is a novel oral, small molecule inhibitor of amyloid aggregation and neurotoxicity with potential to be a first-in-class therapy for a genetically defined population of patients with or at high risk for Alzheimer’s disease.

“We are pleased to obtain this Japanese patent which further strengthens our robust intellectual property surrounding ALZ-801 in another major market, building on our issued U.S. patents,” said Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive Officer of Alzheon. “We are building a strong foundational patent estate for ALZ-801 in important global pharmaceutical markets, as we position Alzheon to execute on our plans to advance this innovative product candidate into a potentially pivotal study in Alzheimer’s disease in the near future.”

About Alzheon
Alzheon, Inc., a clinical-stage biotechnology company focused on brain health, memory and aging, develops innovative treatments for Alzheimer’s disease and other neurological and psychiatric disorders. The company pursues product candidates for which there is evidence of both target engagement and clinical safety and efficacy, and where new insights and development strategies can be applied. Alzheon’s lead product candidate, ALZ-801, is an oral small molecule inhibitor of amyloid aggregation and neurotoxicity with potential to be a firstin-class oral therapy for a genetically defined population of patients with or at high risk for Alzheimer’s disease.

Media Contact:
Kathryn Morris
The Yates Network
845-635-9828
kathryn@theyatesnetwork.com

2016-11-18T12:35:31+00:00 September 5th, 2014|